Search

Search Constraints

You searched for: Author/Creator Rodriguez, Maria Alma

Search Results

2. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. (18th June 2014)

3. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Issue 1 (2nd January 2021)

4. Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. Issue 1 (2nd January 2021)

6. Integration of patient-reported outcomes into survivorship care. Issue 28 (1st October 2022)

7. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐Hodgkin lymphomas. (27th June 2013)

8. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Issue 4 (3rd April 2018)

9. Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. Issue 1 (2nd January 2016)

10. Prospective phase II study of rituximab with alternating cycles of hyper‐CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B‐cell lymphoma. (1st October 2013)